This post was originally published on this site
SILVER SPRING, Md., March 07, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2023.
Business Highlights:
- Achieved strong annual revenue growth for both proprietary product lines, with sales increasing for SimpliDerm by 38% and CanGaroo by 3.4%.
- Submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (“FDA” or “Agency”) for CanGarooRM, Elutia’s next-generation drug-eluting biomatrix product.
- FDA review and interaction for CanGarooRM has resulted in no requests for additional data to date. The Company remains on track for a clearance decision in the first half of 2024.
- Successfully closed the divestiture of the orthobiologics business, generating gross cash proceeds of $14.6 million.
- Established a Strategic Advisory Committee of industry experts to prepare for commercial launch of CanGarooRM.
“After years of pioneering development, we are on the verge of introducing the drug-eluting biomatrix that promises to remove compromise from patient care,” stated Dr. Randy Mills, Elutia’s Chief Executive Officer. “In 2023, we completed the groundwork for our flagship product, CanGarooRM, resulting in a high-quality submission to FDA. Since then, our interactions with the Agency have been positive, and we look forward to a clearance decision in the first half of this year.”
Dr. Mills continued, “I’d like to thank our dedicated commercial and operational teams, who, throughout this process, have stayed laser-focused, delivering robust sales figures across our SimpliDerm and CanGaroo product lines. They are now focused on a coordinated and disciplined product rollout of CanGarooRM, ensuring its full potential is realized.”
CanGarooRM Update
In December 2023, Elutia submitted a 510(k) premarket notification to the FDA for CanGarooRM following a successful pre-submission meeting with the FDA. The Company is in ongoing discussions with FDA regarding the submission. To date, clarification requests from the Agency have been limited to items within the new submission, and no additional data has been requested. Elutia expects the FDA’s clearance decision in the first half of 2024 and is preparing for commercial launch.
CanGarooRM is uniquely positioned for success in the drug-eluting envelope market, estimated at over $600 million annually in the United States. As the second market entrant and the only product offering a combination of a biological envelope and potent antibiotics, CanGarooRM is poised to compete effectively. Surgeons particularly appreciate the handling characteristics of a natural biological product. Elutia has developed a focused launch plan, leveraging the Company’s proprietary sales force and distribution network. The Company’s commercial team, equipped with extensive product knowledge and experience, is ready to engage healthcare professionals to drive adoption.
2023 Financial Results
For the year ended December 31, 2023, as compared to 2022 (where applicable):
- Overall net sales were $24.7 million, compared to $23.8 million. The increase was driven by a $2.8 million increase in Women’s Health sales and a $0.3 million increase in Device Protection. Growth in Women’s Health and Device Protection was partially offset by a reduction in sales in the Cardiovascular line of business due to the commencement of the Company’s distribution agreement with LeMaitre Vascular, which provides for sales at a contracted price to the distributor, whereas sales prior to such agreement were made at end-user pricing.
- Gross margin on a GAAP basis, which includes amortization of acquired intangible assets, was 45%, compared to 49%. The reduction was primarily due to the commencement of the LeMaitre Vascular distribution agreement described above.
- Adjusted gross margin (a non-GAAP measure that excludes amortization of acquired intangible assets) was 58%, compared to 63%. A reconciliation of adjusted gross margin to gross margin is provided in the financial tables below.
- Total operating expenses were $41.6 million, compared to $46.8 million. The reduction resulted from efforts to optimize the Company’s operations, primarily in sales and marketing and research and development.
- Net loss was $37.7 million, compared to a net loss of $32.9 million.
- Adjusted EBITDA (a non-GAAP measure) was a loss of $14.6 million, compared to a loss of $22.9 million, reflecting the significant improvement in the Company’s operational performance. Adjusted EBITDA excludes from net loss certain non-operating, non-cash and non-recurring items. A reconciliation of adjusted EBITDA to net loss is provided in the financial tables below.
- Cash was $19.3 million as of December 31, 2023.
Fourth Quarter 2023 Financial Results
For the three-month period ended December 31, 2023, as compared to the same period of 2022:
- Overall net sales were $5.9 million, compared to $6.6 million. The decrease of 11% was primarily due to a $1.3 million decrease in sales of Cardiovascular products resulting from the commencement of the LeMaitre Vascular distribution relationship, partially offset by a $0.8 million increase in SimpliDerm sales.
- Gross margin on a GAAP basis was 36%, compared to 47%. The year-over-year reduction was primarily due to the commencement of the LeMaitre Vascular distribution relationship for the Company’s Cardiovascular products.
- Adjusted gross margin (a non-GAAP measure) was 51%, compared to 59%.
- Total operating expenses were $10.6 million, compared to $12.6 million.
- Net loss was $9.3 million, compared to a net loss of $5.4 million.
- Adjusted EBITDA (a non-GAAP measure) was a loss of $4.5 million, compared to a loss of $4.6 million.
Conference Call
Elutia will host a conference call today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2023 financial results and performance.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13744499
Individuals interested in listening to the conference call are required to register online. Participants are recommended to log in approximately 10 minutes before the start of the call. A live and archived webcast of the event and the accompanying presentation materials will be available on the “Investors” section of the Elutia website at investors.elutia.com.
About Elutia
Elutia develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Non-GAAP Disclosure
In addition to the Company’s financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents in this press release the following non-GAAP financial measures: earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”), adjusted gross margin and adjusted gross profit. The Company defines EBITDA as GAAP net loss excluding interest expense, income tax expense, depreciation and amortization, and the Company defines adjusted EBITDA as EBITDA excluding income from discontinued operations, stock-based compensation, FiberCel litigation costs, loss on extinguishment of debt, net of gain on debt forgiveness, loss on revaluation of warranty liability and gain on revaluation of revenue interest obligation. The Company defines adjusted gross profit and adjusted gross margin as GAAP gross profit and GAAP gross margin, respectively, excluding amortization of acquired intangible assets. The amortization of these intangible assets will recur in future periods until such intangible assets have been fully amortized. Management believes that presentation of non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. The Company uses this non-GAAP financial information to establish budgets, manage the Company’s business, and set incentive and compensation arrangements. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For a reconciliation of these non-GAAP measures to GAAP, see below “Non-GAAP Reconciliations of EBITDA and Adjusted EBITDA” and “Non-GAAP Reconciliations of Adjusted Gross Profit and Adjusted Gross Margin.”
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning our results of operations, financial position, and business strategy; expectations regarding our products and their targeted effects; plans for our sales and marketing growth; expectations regarding our recently completed sale of our Orthobiologics Business to Berkeley Biologics, LLC (“Berkeley”), including potential payment of post-closing earnout payments; our anticipated expansion of our product development and research activities; increases in expenses and seasonality; expectations regarding our competitive advantages, and overall clinical and commercial success; expectations regarding the pending lawsuits and claims related to our recall of a single lot of Fiber Viable Bone Matrix (“FiberCel”), amounts recoverable under insurance, indemnity and contribution agreements and the impact of such lawsuits and claims on our future financial position; expectations regarding the potential emergence of lawsuits, claims and regulatory findings related to our recall of a single lot of the viable bone matrix (“VBM”) products, amounts recoverable under insurance, indemnity and contribution agreements and the impact of such lawsuits and claims on our future financial position; our expectations and plans regarding pursuit of any strategic transactions; and our expectations relating to the U.S. Food and Drug Administration (“FDA”) regulatory process for the CanGarooRM® Antibacterial Envelope, including our expectations with respect to the timing and outcome of any FDA approval decisions, and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2022, as such factors may be updated from time to time in Elutia’s other filings with the SEC, including Elutia’s Quarterly Reports on Form 10-Q, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
| ELUTIA INC. | ||||||||||
| CONSOLIDATED BALANCE SHEET DATA | ||||||||||
| (Unaudited, in thousands) | ||||||||||
| Assets | December 31, 2023 | December 31, 2022 | ||||||||
| Current assets: | ||||||||||
| Cash | $ | 19,276 | $ | 16,989 | ||||||
| Accounts receivable, net | 3,263 | 3,774 | ||||||||
| Inventory | 3,853 | 4,240 | ||||||||
| Receivables of FiberCel litigation costs | 2,696 | 13,813 | ||||||||
| Prepaid expense and other assets | 2,165 | 2,387 | ||||||||
| Current assets of discontinued operations | – | 9,496 | ||||||||
| Total current assets | 31,253 | 50,699 | ||||||||
| Property and equipment, net | 172 | 245 | ||||||||
| Intangible assets, net | 11,671 | 15,069 | ||||||||
| Operating lease right-of-use assets, and other | 332 | 320 | ||||||||
| Noncurrent assets of discontinued operations | – | 2,508 | ||||||||
| Total assets | $ | 43,428 | $ | 68,841 | ||||||
| Liabilities and Stockholders’ Deficit | ||||||||||
| Current liabilities: | ||||||||||
| Accounts payable and accrued expenses and other current liabilities | $ | 12,676 | $ | 11,104 | ||||||
| Current portion of long-term debt and revenue interest obligation | 15,062 | 8,990 | ||||||||
| Contingent liability for FiberCel litigation | 15,024 | 17,360 | ||||||||
| Current operating lease liabilities | 275 | 232 | ||||||||
| Current liabilities of discontinued operations | – | 4,929 | ||||||||
| Total current liabilities | 39,796 | 42,615 | ||||||||
| Long-term debt | 20,356 | 24,260 | ||||||||
| Long-term revenue interest obligation | 5,360 | 5,916 | ||||||||
| Warrant liability in connection with PIPE offering | 12,760 | – | ||||||||
| Other long-term liabilities | 515 | 127 | ||||||||
| Noncurrent liabilities of discontinued operations | – | 956 | ||||||||
| Total liabilities | 82,028 | 73,874 | ||||||||
| Stockholders’ equity (deficit): | ||||||||||
| Common stock | 23 | 16 | ||||||||
| Additional paid-in capital | 137,021 | 132,939 | ||||||||
| Accumulated deficit | (175,644 | ) | (137,988 | ) | ||||||
| Total stockholders’ equity (deficit) | (38,600 | ) | (5,033 | ) | ||||||
| Total liabilities and stockholders’ equity | $ | 43,428 | $ | 68,841 | ||||||
| ELUTIA INC. | |||||||||||||||
| CONSOLIDATED STATEMENT OF OPERATIONS | |||||||||||||||
| (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three months ended December 31, | Twelve months ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net sales | $ | 5,875 | $ | 6,592 | $ | 24,745 | $ | 23,849 | |||||||
| Cost of goods sold | 3,751 | 3,526 | 13,692 | 12,210 | |||||||||||
| Gross profit | 2,124 | 3,066 | 11,053 | 11,639 | |||||||||||
| Operating expenses: | |||||||||||||||
| Sales and marketing | 2,572 | 4,178 | 13,087 | 17,850 | |||||||||||
| General and administrative | 3,967 | 3,263 | 14,104 | 16,051 | |||||||||||
| Research and development | 1,381 | 1,860 | 4,399 | 7,727 | |||||||||||
| FiberCel litigation costs | 2,711 | 3,292 | 9,989 | 5,200 | |||||||||||
| Total operating expenses | 10,631 | 12,593 | 41,579 | 46,828 | |||||||||||
| Loss from continuing operations | (8,507 | ) | (9,527 | ) | (30,526 | ) | (35,189 | ) | |||||||
| Interest expense | 1,511 | 1,452 | 5,796 | 5,118 | |||||||||||
| Other (income) expense, net | 5,211 | (4,962 | ) | 4,899 | (4,159 | ) | |||||||||
| Loss before provision for income taxes | (15,229 | ) | (6,017 | ) | (41,221 | ) | (36,148 | ) | |||||||
| Provision for income taxes | (8 | ) | (2 | ) | 28 | 34 | |||||||||
| Net loss from continuing operations | (15,221 | ) | (6,015 | ) | (41,249 | ) | (36,182 | ) | |||||||
| Income from discontinued operations | 5,905 | 575 | 3,593 | 3,285 | |||||||||||
| Net Loss | (9,316 | ) | (5,440 | ) | (37,656 | ) | (32,897 | ) | |||||||
| Net loss from continuing operations per share | |||||||||||||||
| basic and diluted | $ | (0.66 | ) | $ | (0.42 | ) | $ | (2.27 | ) | $ | (2.62 | ) | |||
| Net income (loss) from discontinued operations per share | |||||||||||||||
| basic and diluted | $ | 0.25 | $ | 0.04 | $ | 0.20 | $ | 0.24 | |||||||
| Weighted average common shares outstanding – | |||||||||||||||
| basic and diluted | 23,195,190 | 14,468,823 | 18,160,822 | 13,832,887 | |||||||||||
| ELUTIA INC. | |||||||||||||||
| NON-GAAP RECONCILIATIONS OF ADJUSTED GROSS PROFIT AND ADJUSTED GROSS MARGIN | |||||||||||||||
| (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three months ended December 31, | Twelve months ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net sales | $ | 5,875 | $ | 6,592 | $ | 24,745 | $ | 23,849 | |||||||
| Gross profit | 2,124 | 3,066 | 11,053 | 11,639 | |||||||||||
| Intangible asset amortization expense | 851 | 850 | 3,398 | 3,398 | |||||||||||
| Adjusted gross profit (Non-GAAP) | $ | 2,975 | $ | 3,916 | $ | 14,451 | $ | 15,037 | |||||||
| Gross margin | 36.2 | % | 46.5 | % | 44.7 | % | 48.8 | % | |||||||
| Adjusted gross margin percentage (Non-GAAP) | 50.6 | % | 59.4 | % | 58.4 | % | 63.1 | % | |||||||
| ELUTIA INC. | |||||||||||||||
| NON-GAAP RECONCILIATIONS OF EBITDA AND ADJUSTED EBITDA | |||||||||||||||
| (Unaudited, in thousands, except share and per share data) | |||||||||||||||
| Three months ended December 31, | Twelve months ended December 31, | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| Net loss | $ | (9,316 | ) | $ | (5,440 | ) | $ | (37,656 | ) | $ | (32,897 | ) | |||
| Interest expense (1) | 1,511 | 1,452 | 5,796 | 5,118 | |||||||||||
| Provision (benefit) for income taxes | (8 | ) | (2 | ) | 28 | 34 | |||||||||
| Depreciation and amortization | 868 | 919 | 3,618 | 3,566 | |||||||||||
| Earnings before interest, taxes, depreciation and amortization (“EBITDA”) (Non-GAAP) | (6,945 | ) | (3,071 | ) | (28,214 | ) | (24,179 | ) | |||||||
| Income from discontinued operations | (5,905 | ) | (575 | ) | (3,593 | ) | (3,285 | ) | |||||||
| Stock-based compensation | 424 | 750 | 2,296 | 3,503 | |||||||||||
| FiberCel litigation costs (2) | 2,711 | 3,292 | 9,989 | 5,200 | |||||||||||
| Loss on extinguishment of debt, net of gain on debt forgiveness (3) | – | – | – | 803 | |||||||||||
| Loss on revaluation of warranty liability (4) | 5,210 | – | 4,898 | – | |||||||||||
| Gain on revaluation of revenue interest obligation (5) | – | (4,962 | ) | – | (4,962 | ) | |||||||||
| Adjusted EBITDA (Non-GAAP) | $ | (4,505 | ) | $ | (4,566 | ) | $ | (14,624 | ) | $ | (22,920 | ) | |||
| (1) Represents interest expense recorded on all outstanding long-term debt as well as the revenue interest obligation. | |||||||||||||||
| (2) Represents FiberCel litigation costs consisting primarily of legal fees and the estimated and actual costs to resolve the outstanding FiberCel litigation cases offset by the estimated amounts recoverable and recovered under insurance, indemnity and contribution agreements for such costs. | |||||||||||||||
| (3) Represents loss related to debt refinancing in August 2022 and the associated prepayment fees, payment of unaccrued exit fees and the write-off of unamortized deferred financing costs, which collectively resulted in a loss of $1.2 million. Such loss was offset by other income of $0.4 million related to the forgiveness of interest accrued on the promissory note to a tissue supplier upon repayment of such note in August 2022. | |||||||||||||||
| (4) Represents non-cash expense attributable to the revaluation of Common Warrants and Prefunded Warrants issued in connection with a private offering of Class A common stock on September 21, 2023. | |||||||||||||||
| (5) Represents the gain on the revaluation of the revenue interest obligation. At each reporting period, the value of the revenue interest obligation is re-measured based on current estimates of future payments, with changes to be recorded in the consolidated statements of operations using the catch-up method. | |||||||||||||||
